PraXsyn Corporation (OTCB: PAWS) is dedicated to providing medical practitioners with medications and services for their patients. We currently formulate transdermal creams and ointments in our compounding pharmacy, Mesa Pharmacy. These are geared to patients suffering from long-term pain associated with work place related injuries. In the near future, we will be instituting our Point of Care/In-Office Dispensing Program, and our In-Office Toxicology Testing. As the medical industry changes, PraXsyn Corporation will be there to provide different delivery systems.
PALO ALTO, CA, April 23, 2014 -- The PAWS Pet Company, Inc. (OTCQB: PAWS), announces that its 10K filing was submitted to the SEC this afternoon. “We would like to thank our auditors and our financial team that worked around the clock to get it done,” said Dan Wiesel, CEO of The PAWS Pet Company. “With the 10K complete, we are looking forward to filing the 10Q which will incorporate the results of our new merger partner Mesa Pharmacy”.
Company Expects Filing as Early as Today
PraXsyn Name Change Has Been Filed With the State of Illinois and Soon to be Filed With FINRA
John Garbino and Ed Kurtz Join Board of Directors
Name change imminent.
PALO ALTO, CA, April 9, 2014 -- The PAWS Pet Company, Inc. (OTCQB: PAWS), announced it completed the merger of Pharmacy Development Corp. (PDC), the parent company of MESA Pharmacy, Inc. (“Mesa”) into PDC, Inc. (PDCINC), PAWS wholly-owned subsidiary on March 31, 2014.
PALO ALTO, CA, March 12, 2014 - The PAWS Pet Company, Inc. (OTCQB:PAWS), is pleased to announce that revised February orders at its Mesa Pharmacy, Inc. (Mesa) subsidiary generated gross revenues, excluding allowances for returns and discounts, exceeding $7.4 Million Dollars. Prescription orders for transdermal topical pain medications continue to rise.
IRVINE, CA, Feb. 26, 2014 - The PAWS Pet Company, Inc. (OTCQB:PAWS), is pleased to announce that February orders at its Mesa Pharmacy, Inc. (Mesa) subsidiary have continued to increase inline with expectations and have generated gross revenues, excluding allowances for returns and discounts, exceeding $6.5 Million Dollars. "We are currently filling prescriptions for transdermal topical pain medications of approximately $400,000 dollars per day". Stated Andrew Do, Mesa's President and Registered Pharmacist.